TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05765812: A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radio

Sponsor: Debiopharm International SA · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 116 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,356,200

Rescue Site Savings

+$1,570,800

Unlock Full NCT05765812 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05765812 Rescue Dossier →